about
Zika VirusZika Virus and Birth Defects — Reviewing the Evidence for CausalityProjecting Month of Birth for At-Risk Infants after Zika Virus Disease OutbreaksPreventing Zika Virus Infections in Pregnant Women: An Urgent Public Health PriorityInterim Guidelines for Prevention of Sexual Transmission of Zika Virus — United States, 2016Acute flaccid paralysis and West Nile virus infectionChikungunya: epidemiologyInvestigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findingsScreening of Blood Donations for Zika Virus Infection - Puerto Rico, April 3-June 11, 2016Prolonged Detection of Zika Virus RNA in Pregnant WomenWest Nile virus: review of the literatureHigh Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014Highly Sensitive Detection of Dengue Virus Nucleic Acid in Samples from Clinically Ill PatientsHospital-Based Surveillance for Japanese Encephalitis at Four Sites in Bangladesh, 2003-2005The 1.6 A structure of Kunitz-type domain from the alpha 3 chain of human type VI collagenSolution structure and backbone dynamics of the human alpha3-chain type VI collagen C-terminal Kunitz domain,Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue virusesBirth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During PregnancyZika Virus —10 Public Health Achievements in 2016 and Future PrioritiesVital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016Studying the effects of emerging infections on the fetus: Experience with West Nile and Zika virusesDecision making in the face of uncertainty: the challenge of emerging infectious diseasesWest Nile virus infections projected from blood donor screening data, United States, 2003Bartonella tamiae sp. nov., a newly recognized pathogen isolated from three human patients from ThailandNeurologic manifestations and outcome of West Nile virus infection.Risk factors for alveolar echinococcosis in humansTransmission of West Nile virus from an organ donor to four transplant recipients.Tularemia on Martha's Vineyard: seroprevalence and occupational risk.Shifting epidemiology of Flaviviridae.West Nile fever characteristics among viremic persons identified through blood donor screening.Mosquitoes of Western Yunnan Province, China: seasonal abundance, diversity, and arbovirus associations.Assessment of Arbovirus Surveillance 13 Years after Introduction of West Nile Virus, United States.West Nile Virus-associated flaccid paralysis outcome.Cost-effectiveness of West Nile virus vaccination.Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008Coccidioidomycosis among workers at an archeological site, northeastern Utah.West Nile virus economic impact, Louisiana, 2002West Nile virus-associated flaccid paralysis.Cross-sectional study on influenza vaccination, Germany, 1999-2000.West Nile virus in the Americas.
P50
Q23671721-D6DDFCEC-6988-48D6-A6EC-C74D9C816EB7Q23815222-34A8B146-9B1E-4529-B44C-4A328913F7A9Q24261128-1671DE63-9855-4D15-8BCA-12751C51FECAQ24261133-CD434325-AACE-4F3C-9223-83544A45E8CDQ24261165-5D302AD0-06D9-45C0-BCD8-A07DFB8AC9ACQ24594634-F84739FA-2A62-4437-B669-03244DD62F5EQ24701719-15CBEC25-F5EA-41BE-A51E-D8776AE55554Q24718884-C519F602-2054-4A9C-9E07-BC0D83AC3F75Q25019015-878fdc94-4477-10f8-f10d-fd8341799458Q26250264-B0B8620D-4DF9-4E20-AD19-400C5D33ECBFQ26827766-1616A278-0D05-40EF-8475-C4E3C665C0ECQ27468998-5558F06B-E915-4226-AEC0-3CA60240841AQ27488302-A790826D-BC89-48E0-9C50-4823951CE2C5Q27490858-F2D3C1C8-8C5F-47C3-BEED-D11A5727A552Q27729418-7091CB78-2248-4FDE-940F-870353649248Q27742209-5FF6CB88-F3BD-4CAC-8872-2E06DDCF106FQ27860800-CC742011-420B-427A-8C4C-9CCD17C81171Q28005781-4EA166D0-E090-408B-8B7D-FF2AC330213DQ28114568-8864DAE4-D6FE-4CEC-BC41-C6FA26A90D90Q29168666-695C1FC1-FBCB-4413-9B16-22483F8DA2CEQ29365300-B5628F62-2AFF-4804-8E45-725E35FA383DQ29365382-97A5E844-4E6A-4CCC-8142-D81D5F872C09Q31041026-317D231B-D744-41A1-AA90-E4600D9954FAQ31139993-17806521-3C17-4174-8576-2E5EE2136707Q33967282-1E6FC4CB-B365-4246-B64F-FEBC8987B345Q33984481-913B7DD8-DA65-44F8-8FC1-D7E34403AEA1Q34201110-8B59EFBB-B995-491D-89C3-12780EAC5B48Q34219247-F871E0AC-AF2B-491C-BFAA-9A25E0E6A99CQ34561748-E8209804-FB1E-40DB-B3C1-AA968D88AEF0Q34623850-57B86CA5-8052-4F8E-8356-1420019CEBFCQ35023025-80B9D05C-5929-4BB0-BCAD-D4A5DB8939D1Q35780205-D623353D-CD88-4C9B-B693-F1A2D260177DQ35793924-6CF5AA40-B806-452F-9F1D-5FB60040E62DQ35793943-A3F4F092-EAF5-43CA-B845-E629C0147C06Q35844722-72431DA5-9D97-4247-924A-9B48AA642692Q35880153-08CF0E98-6628-4CFD-9081-2EC9ABF39CD2Q35880823-05DED9E0-11A7-41F6-98B5-87BE9278D99EQ36021961-5FE12C48-F4BB-4120-A623-A37AE869B380Q37334447-AFEB19E1-BA04-422A-80A9-3935EC1C06C4Q37369061-4EE3758D-1FAC-43DB-BFC3-E43F28271107
P50
description
physician
@en
viroloog
@nl
name
Lyle R. Petersen
@ast
Lyle R. Petersen
@en
Lyle R. Petersen
@es
Lyle R. Petersen
@nl
type
label
Lyle R. Petersen
@ast
Lyle R. Petersen
@en
Lyle R. Petersen
@es
Lyle R. Petersen
@nl
altLabel
L R Petersen
@en
L. R. Petersen
@en
Lyle Petersen
@en
Lyle R Petersen
@en
prefLabel
Lyle R. Petersen
@ast
Lyle R. Petersen
@en
Lyle R. Petersen
@es
Lyle R. Petersen
@nl